Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

BACKGROUND: Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human colorectal cancer (CRC) previously treated with conventional chemotherapy would be sensitive to T-cell killing mediated by carcinoembryonic antigen (CEA)/CD3-bispecific...

Descripción completa

Detalles Bibliográficos
Autores principales: Osada, T, Hsu, D, Hammond, S, Hobeika, A, Devi, G, Clay, T M, Lyerly, H K, Morse, M A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813763/
https://www.ncbi.nlm.nih.gov/pubmed/19953093
http://dx.doi.org/10.1038/sj.bjc.6605364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813763/
https://www.ncbi.nlm.nih.gov/pubmed/19953093
http://dx.doi.org/10.1038/sj.bjc.6605364

Ejemplares similares